Is there a life-threatening situation after the targeted drug is resistant? How to check?
Resistance to the targeted drug was not necessarily life-threatening. After drug resistance, treatment could be continued in a variety of ways to control the development of the disease, such as changing medicine, chemotherapy, etc. After active treatment, the disease could be effectively controlled, the quality of life could be improved, and the survival time could be extended. To determine whether the targeted drug was resistant, the following aspects could be examined: First, observe the patient's symptoms and treatment response. If the original symptoms did not improve or even worsened after receiving targeted drug treatment for a period of time, it might mean that drug resistance had developed. Second, through the relevant examinations conducted by the doctor regularly, such as imaging examinations, blood tests, etc., these examination results could help monitor the changes in the condition and the efficacy of the drug, so as to determine whether the drug was resistant. Third, it was judged according to the specific drug resistance mode. For example, when the drug resistance was slow, the tumor might not be reduced and the tumor marker might be increased; when the drug resistance was partial, there might be some parts that were well controlled but there might be other parts of the tumor. When the drug resistance was complete, the reexamination would find that the tumor was growing, the marker was increased, there might be other parts of the tumor that had metastasized, and the patient's body sensation would change greatly, such as pain, cough, dizziness, etc. Read more exciting novels for free
Take the third generation of targeted drugs after the first generation of targeted drugs are resistant
After the first-generation targeted drug became resistant, the third-generation targeted drug could be considered. According to the data in document [2], after the first-generation targeted drug became resistant, only about 25% of patients had the opportunity to use osimertinib for second-line treatment. According to the study mentioned in document [4], the first-line use of osimertinib for the treatment of egfr-positive lung cancer, followed by comprehensive treatment methods such as chemotherapy and chemotherapy after drug resistance, the patient's overall survival time was 41.4 months, which was twice as long as the first-generation targeted drug. In addition, the document [5] mentioned the dual-target combination therapy plan, specifically the first-line treatment of the third-generation TKi osimertinib combined with the first-generation TKi gefitini, with a disease control rate of 100%. Therefore, for patients who were resistant to first-generation targeted drugs, third-generation targeted drugs might be an effective treatment option.
Brain tumor 2024 latest targeted drug
In 2024, there were some advancements in targeted drugs related to brain tumors: - Buritini: On April 23, 2024, it was approved in China for IDH mutant astrocytomas (World Health Organization grade 4) with the PTHRZ1-MET fusion gene or adult patients with glioblastomas with a low-grade medical history. This was the first fully approved small molecular targeted drug in the field of MET-targeted therapy for gliomas in China. In February 2021 and September 2022, the indications for lung cancer and gliomas were included as breakthrough treatments by the Center for Drug Evaluation (CDEs) of China's NMPA. The first indication was approved in November 2023 for the treatment of adult patients with locally advanced or metastasized non-small cell lung cancer (Lung cancer) with MET 14 mutation. - Servier's Voranigo (vorasidenib): approved by the US Food and Drug Administration on August 6, 2024, for the treatment of adult and child patients aged 12 years and older with grade 2 astrocytomas or oligodrenogliomas that are susceptible to IDH1 or IDH2 mutations. This is the first time that this type of grade 2 IDH-mutated brain cancer has been approved as a full-body therapy. Hurry up and click on the link below to return to the super classic "Lord of the Mysteries"!
Is there a targeted drug for the spread of cervical cancer?
Yes. For example, anti-VegG drugs (such as bevacizhu), VegG is a pro-inflammatory factor that can promote the growth and spread of olive cancer cells, bevacizhu can block the binding of VegG to its receptor, and suppress the growth and migration of olive cancer cells;Parp inhibition drugs (such as olaparib) can prevent olive cancer cells from undergoing the correct DNA repair process, causing serious genetic mutations in cancer cells and death; ATR inhibition drugs (such as VE - 822). ATR is an important molecular response to DNA damage in cells. It will be activated after DNA double-strand breaks. VE - 822 can selectively inhibit ATR and promote the death of malignant tumor cells. Anti-HEL2 drugs (such as tocilbizumb). HEL2 is a targeted protein that is highly expressed in some patients with malignant tumors. Tocilbizumb can bind to HEL2 and suppress the growth and spread of malignant tumors. These targeted drugs could be combined with traditional surgery or chemotherapy to improve the treatment effect of the spread of the cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What is a novel way to fight drug resistant bacteria?
One possible novel way could be the use of targeted phage therapy. Phages are viruses that specifically attack bacteria and could potentially be engineered to target drug-resistant strains.
Is there a targeted drug in the ribs of cardiac cancer metastasizing?
Cardia cancer with rib metastasizing was stage IV. For this case, Folfox protocol chemotherapy + anti-neoplastic drugs such as bevacizumi or cetuxed targeted therapy could be used. In addition, targeted drugs for the treatment of cardiac cancer also included erlotinib, gefitinib, nimotuzumab, pembrolizub, and so on. However, different targeted drugs had their own applications. For example, erlotinib was suitable for the treatment of patients with locally advanced, relapsed, or metastasized non-small cell lung cancer with mutations in the egF-receptor protein protein gene; Gefitini was used for the treatment of patients with locally advanced or metastasized non-small cell lung cancer who had failed at least one prior chemotherapy; Cetuxed was suitable for patients with wild-type RAS gene in the Coloreceptor Cancer; Nimotubiza is indicated for the auxiliary treatment of patients with stage III non-small cell lung cancer with positive expression of the Epidermal Growth factor receptor; pembrolizub is indicated for adult patients with positive expression of PD-L1 or anplastic large cell leukemia who have progressed during or after first-line systematic chemotherapy. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there reimbursement for Changde lung cancer targeted drug?
Based on the information provided so far, it was impossible to determine whether Changde's targeted lung cancer drug was eligible for reimbursement. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there a targeted drug for grade 3 brain stem gliomas?
The more commonly used gliomas targeted drugs were bevacizumi, anlotinib, imatini, gefitini, bevacizumi, and PD - 1. These drugs could be used for targeted therapy of gliomas, and may also be suitable for grade 3 brainstem gliomas. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is the targeted drug for liver cancer metastasizing useful?
If liver cancer patients had metastasized, they could use targeted drugs, but they had to pay attention to their own condition. For patients with liver cancer lung metastasizing, they could take targeted drugs such as sorafenib, gefitini, or afatini. Sorafenib was more commonly used to treat untreatable or distant cancerous tumors. However, if there was severe liver function decline, large amounts of ascitic fluid, digestive tract bleeding, hepatic epilepsy, repeated infection, and other conditions, it was not suitable to use targeted drugs. At the same time, although targeted drugs had a certain effect on many liver cancer patients, some patients had no effect at all, and the cost was relatively high. Therefore, it was necessary to choose according to the individual's actual situation. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there an imitation of the targeted drug for cervical cancer in India?
Yes, there was an Indian imitation version of the targeted drug. For example, there was an Indian version of Niraparini, but its price was difficult for ordinary family patients to afford. A box of Indian version of Niraparini cost about 20000 yuan. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Fanfiction about Tenten protecting Naruto in a life - threatening situation.
In the fanfiction, Naruto might be targeted by a powerful enemy who wants to steal his Nine - Tails chakra. Tenten, being a skilled ninja, steps in to protect him. She could set up all kinds of traps around their hiding place using her weaponry skills, and engage in combat with the enemy when they get too close, buying time for Naruto to regain his strength or for backup to arrive.